IMIQUIMOD FOR BCC

IMPORTANCE OF PATIENT ORIENTATED TREATMENT OPTIONS

1. Venning, V.L., et al., *Keratinocyte carcinoma as a chronic disease in Australia and Spain: The importance of avoidance of perceived visible scars.* Australas J Dermatol, 2019. **60**(4): p. 284-287.

TREATMENT OF BCC WITH CURETTAGE ALONE

2. Barlow, J.O., et al., *Treatment of basal cell carcinoma with curettage alone.* J Am Acad Dermatol, 2006. **54**(6): p. 1039-45.
3. Patel, S.S., S.H. Cliff, and P. Ward Booth, *Incomplete removal of basal cell carcinoma: what is the value of further surgery?* Oral Maxillofac Surg, 2013. **17**(2): p. 115-8.

TREATMENT OF BCC WITH IMIQUIMOD ALONE

4. Peris, K., et al., *Imiquimod treatment of superficial and nodular basal cell carcinoma: 12-week open-label trial.* Dermatol Surg. 2005;31(3):318-323.
5. Huang, C.M. and M.G. Kirchhof, *Topical Imiquimod as a Treatment Option for Nodular Basal Cell Carcinoma: A Systematic Review.* J Cutan Med Surg, 2020. **24**(5): p. 495-503.

IMIQUIMOD VS OTHER NONSURGICAL TREATMENTS FOR BCC

5. Arits, A.H.M.M., et al., *Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomized controlled trial.* The Lancet Oncology, 2013. **14**(7): p. 647-654.
6. Jansen, M.H.E., et al., *Five-Year Results of a Randomized Controlled Trial Comparing Effectiveness of Photodynamic Therapy, Topical Imiquimod, and Topical 5-Fluorouracil in Patients with Superficial Basal Cell Carcinoma.* J Invest Dermatol, 2018. **138**(3): p. 527-533.
7. Shaw, F.M. and M.A. Weinstock, *Comparing Topical Treatments for Basal Cell Carcinoma.* J Invest Dermatol, 2018. **138**(3): p. 484-486.

IMIQUIMOD VS. SURGERY

8. Bath-Hextall, F., et al., *Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicenter, non-inferiority, randomized controlled trial.* The Lancet Oncology, 2014. **15**(1): p. 96-105.
9. Williams, H.C., et al., *Surgery Versus 5% Imiquimod for Nodular and Superficial Basal Cell Carcinoma: 5-Year Results of the SINS Randomized Controlled Trial.* J Invest Dermatol, 2017. **137**(3): p. 614-619.

COMBINED TREATMENT: CURETTAGE AND IMIQUIMOD

10. Wu, J.K., et al., *An open-label, pilot study examining the efficacy of curettage followed by imiquimod 5% cream for the treatment of primary nodular basal cell carcinoma.* Australas J Dermatol, 2006. **47**(1): p. 46-8.
11. Tillman D.K. Jr., et al., *A 36-month clinical experience of the effectiveness of curettage and imiquimod 5% cream in the treatment of basal cell carcinoma.* J Drugs Dermatol. 2008;7(1 Suppl 1):s7-s14.
12. Rigel, D.S., et al., *Imiquimod 5% cream following curettage without electrodesiccation for basal cell carcinoma: preliminary report.* J Drugs Dermatol. 2008;7(1 Suppl 1):s15-s16.

RECENT GUIDELINES

13. Work, G., et al., *Guidelines of care for the management of basal cell carcinoma.* J Am Acad Dermatol, 2018. **78**(3): p. 540-559.
14. Peris, K., et al., *Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines.* Eur J Cancer, 2019. **118**: p. 10-34.

ALTERNATIVE DOSING REGIMENS

15. Stockfleth, E., et al., *Topical resiquimod dosing regimens in patients with multiple actinic keratoses: a multicentre, partly placebo-controlled, double-blind clinical trial.* Br J Dermatol, 2019. **180**(2): p. 297-305.
16. Guitera, P., et al., *A practical guide on the use of imiquimod cream to treat lentigo maligna.* Australas J Dermatol, 2021. **62**(4): p. 478-485.